^
Association details:
| Biomarker: | CTNNB1 S45P |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | foscenvivint (PRI724) (CBP inhibitor, β-catenin inhibitor, Wnt signalling pathway inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2886 / 24 - Investigation of tumor-intrinsic activated Wnt/B-catenin signaling in immune avoidance of HCC
Published date:
03/15/2023
Excerpt:
After a week of ICG-001 treatment by continuous osmotic pump perfusion, 42.9% (6/14) of CTNNB1 (S45P) mice showed a positive response to ICG-001, where a tumor regressed volume was indicated in 4 mice and stable disease in 2 mice….Based on these findings, it is plausible that CTNNB1 activation impairs the expression of chemoattractant in HCC, and prevents immune cell migration into the tumor site.
